Bin P, Boddy A V, English M W, Pearson A D, Price L, Tilby M J, Newell D R
Cancer Research Unit, Medical School, University of Newcastle upon Tyne, U.K.
Anticancer Res. 1994 Nov-Dec;14(6A):2279-83.
Cisplatin and carboplatin are important drugs in the treatment of childhood cancers. Extensive data for carboplatin, and more limited results with cisplatin, indicate that there is significant inter-patient pharmacokinetic variability such that adaptive dosing may be necessary for the optimal use of these drugs. Glomerular filtration rate based dosing formulae have been developed for carboplatin and their use is reviewed. Further studies are needed with cisplatin in order to define the reasons for inter-patient pharmacokinetic variability and its relevance in clinical practice. Only very limited data are available on the clinical or molecular pharmacodynamics of cisplatin and carboplatin in paediatric patients. By analogy with adult studies, pharmacologically-guided platinum complex treatment should offer significant advances over empiric dosing.
顺铂和卡铂是治疗儿童癌症的重要药物。关于卡铂的大量数据以及关于顺铂的较为有限的结果表明，患者间存在显著的药代动力学变异性，因此为了这些药物的最佳使用，可能需要进行适应性给药。已经开发出基于肾小球滤过率的卡铂给药公式，并对其应用进行了综述。对于顺铂，还需要进一步研究以确定患者间药代动力学变异性的原因及其在临床实践中的相关性。关于顺铂和卡铂在儿科患者中的临床或分子药效学，仅有非常有限的数据。类比成人研究，药理学指导的铂类复合物治疗应比经验性给药有显著进展。
